SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, apparently newsless XCN spike is driving attention, with traders debating whether it is a fleeting pump-and-dump or a rebound worth buying. Some point to Bitcoin turning green and bullish chart patterns, while others cite XCNs history of quick spikes followed by drops.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Attention centers on reports that Papa Johns largest U.S. franchisee has joined Irth Capitals effort to take the company private. Traders are hopeful a deal could materialize, but uncertainty over the boards response and whether the bid will close remains a point of debate.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds quarterly results and weaker profit outlook are drawing attention: elevated jet-fuel costs are squeezing margins despite strong revenue and travel demand. Traders are split between viewing the demand and pricing strength as supportive and worrying that fuel expenses will keep weighing on earnings.

Permian Resources Corp. is an oil and natural gas company, which focuses on returns to stakeholders through the responsible acquisition, optimization and development of crude oil and associated liquids-rich natural gas reserves. The company was founded on December 18, 2025 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is drawing attention amid volatile oil prices and Middle East supply concerns, especially disruptions and uncertainty around the Strait of Hormuz and Iran negotiations. Bulls see elevated crude and the companys production growth as supportive, while skeptics point to peace-deal headlines, inventory concerns, and the stocks uneven response to oil moves.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMCs sharply reduced third-quarter outlook, tied to price cuts on distributor-held inventory and weak demand, is driving concern about the companys earnings, debt burden and potential financial distress. Bears fear further deterioration, while bulls argue the reset is largely one-time and point to debt-reduction efforts and a possible longer-term turnaround.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is drawing attention after early Phase 1 azer-cel results in progressive MS showed encouraging safety and disability-stability signals, though traders note the small, uncontrolled study and debate the muted share-price response. Discussion also highlights BRIUMVIs longer-term data and simpler dosing as support for its commercial growth story.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is drawing attention over Phase 3 results for its partnered Moderna melanoma vaccine, which reduced the risk of recurrence or death when added to Keytruda. Traders are weighing the clinically positive data and potential to support Keytruda against high expectations, uncertain commercial prospects and a sell-the-news reaction.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Newly published NEST Phase 2 results for Agenuss BOT+BAL immunotherapy in colorectal cancer are drawing attention, with traders highlighting tumor responses and no observed recurrences. Bulls see encouraging evidence for treatment before surgery, while skeptics stress the small, nonrandomized study and question the path to Phase 3 amid dilution and execution concerns.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on volatile Dow and broader-market moves amid rising Treasury yields, hawkish Fed concerns, and oil and geopolitical risks tied to Iran. Traders are divided between warnings of a deeper selloff and bullish calls for a rebound, with some noting the Dows relative strength versus tech-heavy indexes.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

OXLC is drawing attention amid a sharp selloff and concerns about weaker Core NII and further NAV losses ahead of earnings, with traders pointing to prospectus information and risks in the CLO and lower-quality credit markets. The debate centers on whether the high distribution and potential recovery make the decline a buying opportunity or whether continued NAV erosion and past dividend cuts outweigh the income.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

Execution of Pharma Tariffs Brings These ETFs Into Focus

Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.

Healthcare ETFs Are Looking Up: Here's Why 

Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.

AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights 

Equity

H.C. Wainwright reiterated its ‘Buy’ rating on Omeros after AstraZeneca's Phase 3 setback in HSCT-TMA, saying that the outcome improves Yartemlea's competitive positioning.

ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.


ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.


SPDR Series Trust - State Street SPDR S&P Pharmaceuticals ETF

Neutral Sentiment

<ul class="summary-bullets"><li>AstraZeneca said Ultomiris failed to meet the primary endpoint of event-free survival through 26 weeks in a Phase 3 trial.</li><li>The company said that the study did not demonstrate a statistically significant improvement over placebo.</li><li>Despite the setback, AstraZeneca added it observed a trend toward treatment benefit and plans to continue discussions with health authorities regarding the adult indication.</li></ul>Omeros Corp. (OMER) shares drew investor attention on Monday after analysts at H.C. Wainwright said AstraZeneca's (AZN) late-stage setback for Ultomiris removes the biggest near-term competitive threat to Yartemlea, Omeros' FDA-approved treatment for transplant-associated thrombotic microangiopathy (TA-TMA).According to TheFly, the firm reiterated its ‘Buy’ rating on Omeros, calling AstraZeneca's Phase 3 miss in HSCT-TMA a "clear positive" that removes the key near-term competitive overhang for Yartemlea.<a href="https://stocktwits.com/symbol/OMER">OMER stock</a> was among the top trending tickers on Stocktwits at the time of writing. The stock jumped about 12% in morning trade.&nbsp;<h2 class="st-heading-2">AZN Trial Falls Short</h2>AstraZeneca said Ultomiris failed to meet the primary endpoint of event-free survival through 26 weeks in a Phase 3 trial evaluating the drug in adults and adolescents with TA-TMA.The study did not demonstrate a statistically significant improvement over placebo, the company said.Despite the setback, AstraZeneca added it observed a trend toward treatment benefit and plans to continue discussions with health authorities regarding the adult indication.The company also intends to move forward with regulatory filings for pediatric TA-TMA after a separate Phase 3 trial showed a statistically significant improvement in survival among children treated with Ultomiris.<h2 class="st-heading-2">Where OMER’s Yartemlea Stands</h2>Yartemlea (narsoplimab-wuug) is an FDA-approved inhibitor of the lectin pathway of complement for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children ages 2 years and older.The rare complication can occur following hematopoietic stem cell transplants and has limited approved treatment options.H.C. Wainwright said AstraZeneca's setback improves Yartemlea's competitive positioning in TA-TMA by removing what it viewed as the most significant near-term rival.<h2 class="st-heading-2">HC Wainwright Keeps Focus On US Opportunity For OMER</h2>H.C. Wainwright previously argued that Omeros' long-term investment case hinged on Yartemlea's U.S. commercial potential. Last month, the firm lowered its price target to $33 from $40 after European regulators issued a negative opinion on the therapy, removing the EU opportunity from its valuation model and increasing its research and development spending assumptions.Even then, the firm said the regulatory setback was "not thesis-breaking," maintaining that a potential U.S. launch remained the primary driver of Omeros' value. The latest setback for AstraZeneca's Ultomiris further reinforces that view by easing competitive pressure in the U.S. market, according to the analyst.<h2 class="st-heading-2">What Retail Traders Think Of OMER Stock</h2>Retail sentiment on Stocktwits around Omeros trended in the ‘bullish’ territory at the time of writing.One user believes that Omeros needs transparency more than another bullish narrative.<stembedurl>https://stocktwits.com/lawson12/message/660078253</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> is down 38% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is down 7%. The State Street SPDR S&amp;P Pharmaceuticals ETF (XPH) is up 59% over the past 12 months, while the iShares Russell 2000 Value ETF (IWN) is up 34%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/default/equity/amzn-satellite-network-for-smartphones-what-leo-filing-reveals/cZZxl1FR76J">AMZN Is Building A Satellite Network For Smartphones — Here's What Its Latest Leo Filing Reveals</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Omeros Corp. (OMER) shares drew investor attention on Monday after analysts at H.C. Wainwright said AstraZeneca's (AZN) late-stage setback for Ultomiris removes the biggest near-term competitive threat to Yartemlea, Omeros' FDA-approved treatment for tran

AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights

AstraZeneca PLC

iShares Russell 2000 Value ETF

Omeros Corp

SPDR Pharmaceuticals ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$62.70
Prev Close	$64.28
Open	$63.98
Dividend Yield	N/A
50-Day Moving Average	$67.39
Beta	N/A
Avg. Volume	170,279.59
PE Ratio	N/A

52-Week High	$74.35
52-Week Low	$47.60
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

XPH Fundamentals